Login to Your Account

Neurocrine Signs Blockbuster Deal With Pfizer In Insomnia

By Aaron Lorenzo

Friday, December 20, 2002
The folks at Neurocrine Biosciences Inc. should have slept well last night after potentially earning more than $400 million from the license of a late-stage compound to treat insomnia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription